Telegraph Hill-backed EditCo Bio completed the acquisition of Engineered Cell Solutions Business unit of Synthego.

Telegraph Hill-backed EditCo Bio, a pioneer in the development of cells as reagents, completed the acquisition of Engineered Cell Solutions Business unit of Synthego, a pioneering provider of genome engineering solutions, offering a comprehensive suite of products and services to accelerate CRISPR-based cell and gene therapy development. Financial terms were not disclosed. "EditCo begins its journey with the benefit of significant investment in our cell engineering capabilities while part of Synthego. Our proven products and manufacturing operations enable us to immediately serve customers with industry-leading CRISPR solutions and world-class customer support,” John Tan, Synthego CEO.